The study drug Aimovig is now FDA Approved. MediSphere conducted this Migraine trial in 2015-2017.
Welcome news to some of the millions of Americans who suffer from potentially debilitating migraine headaches! The new drug, Aimovig, was produced by Amgen and approved by the FDA on May 17, 2018. It is the first medicine in a new class that is designed to reduce the number of migraines among people who suffer them frequently.
Aimovig is an expensive type of medication called a monoclonal antibody. It and several other migraine drugs in development, are based on research that begun in the 1980’s. Antibodies are produced in living cells rather than in a chemical laboratory. People inject the drug themselves using a pen like device similar to those used for insulin.
Amgen says it’s ready to put the drug on the market within a week and has programs in place to help ease the cost to some patients.
